Absci (ABSI) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed Mesoblast (MESO) over the past year, gaining 146.5% versus a loss of 22.9%. Over five years, MESO leads with a +22.7% price change compared with -13.3% for ABSI. Mesoblast is the larger company by market cap ($1.79 billion vs $1.53 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | MESO |
|---|---|---|
| Share price | $8.94 | $13.75 |
| Market cap | $1.53B | $1.79B |
| 1-day change | -3.04% | -1.36% |
| YTD return | +164.18% | -22.73% |
| 1-year return | +146.52% | -22.94% |
| 5-year return | -13.26% | +22.71% |
| Forward P/E | — | 30.22 |
| EPS (TTM) | $-0.79 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $21.50 |
| 52-week low | $2.24 | $13.05 |
| Distance from 52-week high | -25.84% | -36.05% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +61.07% | +169.09% |
| Average volume | 3.45M | 232.53K |
| Shares outstanding | 171.61M | 129.85M |
| Employees | 140 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed MESO by 169.5 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
ABSI vs MESO FAQ
Which is bigger, Absci or Mesoblast?
Mesoblast (MESO) is larger, with a market capitalization of $1.79B compared with $1.53B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or MESO?
ABSI returned +146.52% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Mesoblast in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Biological Products (No Diagnostic Substances) for Mesoblast.